The FDA on September 27, 2024, granted traditional approval to RETEVMO® for adult and pediatric patients 2 years of age and older with advanced or metastatic Medullary Thyroid Cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. RETEVMO® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
